Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 11 (November)

1. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
   J Craniomaxillofac Surg, 33(6): 395-403. [Abstract] [Full-text]
2. Outcome of screening by clinical examination of the breast in a trial in the Philippines.
   Int J Cancer, 118(1): 149-54. [Abstract] [Full-text]
3. An inverse association between ovarian cysts and breast cancer in the breast cancer family registry.
   Int J Cancer, 118(1): 197-202. [Abstract] [Full-text]
4. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
   Int J Cancer, 118(1): 103-7. [Abstract] [Full-text]
5. Gene expression profiling in the mammary gland of rats treated with 7,12-dimethylbenz[a]anthracene.
   Int J Cancer, 118(1): 17-24. [Abstract] [Full-text]
6. Episode sensitivity in association with process indicators in the Finnish breast cancer screening program.
   Int J Cancer, 118(1): 174-9. [Abstract] [Full-text]
7. Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells.
   Int J Cancer, 118(1): 35-42. [Abstract] [Full-text]
8. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.
   J Natl Cancer Inst, 97(21): 1609-10. [Abstract] [Full-text]
9. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
   J Natl Cancer Inst, 97(21): 1601-8. [Abstract] [Full-text]
10. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods.
    Cancer Res, 65(21): 10104-12. [Abstract] [Full-text]
11. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations.
    Cancer Res, 65(21): 10096-103. [Abstract] [Full-text]
12. Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells.
    Cancer Res, 65(21): 10024-31. [Abstract] [Full-text]
13. A network of genetic events sufficient to convert normal human cells to a tumorigenic state.
    Cancer Res, 65(21): 9824-8. [Abstract] [Full-text]
14. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
    Cancer Res, 65(21): 9779-88. [Abstract] [Full-text]
15. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy.
    Cancer Res, 65(21): 9741-50. [Abstract] [Full-text]
16. Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers.
    Cancer Res, 65(21): 9727-34. [Abstract] [Full-text]
17. Proteolysis of CCN1 by plasmin: functional implications.
    Cancer Res, 65(21): 9705-11. [Abstract] [Full-text]
18. HIN-1, an inhibitor of cell growth, invasion, and AKT activation.
    Cancer Res, 65(21): 9659-69. [Abstract] [Full-text]
19. Immunohistochemical demonstration of histone H1(0) in human breast carcinoma.
    Histochem Cell Biol, 124(5): 435-43. [Abstract] [Full-text]
20. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors.
    Blood, 106(10): 3358-65. [Abstract] [Full-text]
21. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.
    Clin Chim Acta, 362(1): 125-30. [Abstract] [Full-text]
22. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
    Br J Cancer, 93(10): 1152-6. [Abstract] [Full-text]
23. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.
    Br J Cancer, 93(10): 1128-36. [Abstract] [Full-text]
24. Early neoplastic and metastatic mammary tumours of transgenic mice detected by 5-aminolevulinic acid-stimulated protoporphyrin IX accumulation.
    Br J Cancer, 93(10): 1137-43. [Abstract] [Full-text]
25. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity.
    Br J Cancer, 93(10): 1168-74. [Abstract] [Full-text]
26. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
    Oncogene, 24(49): 7381-8. [Abstract] [Full-text]
27. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
    Oncogene, 24(49): 7281-9. [Abstract] [Full-text]
28. Long-term effects of a standardized complex mixture of urban dust particulate on the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons in human cells in culture.
    Toxicol Sci, 88(2): 358-66. [Abstract] [Full-text]
29. Breast cancer control: signs of progress, but more work required.
    Breast, 14(6): 429-38. [Abstract] [Full-text]
30. Adjuvant endocrine therapies for pre-/perimenopausal women.
    Breast, 14(6): 547-54. [Abstract] [Full-text]
31. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
    Tumour Biol, 26(6): 324-36. [Abstract] [Full-text]
32. Biological variables and prognosis of DCIS.
    Breast, 14(6): 509-19. [Abstract] [Full-text]
33. Adjuvant chemotherapy for breast cancer--"one fits all"?
    Breast, 14(6): 564-9. [Abstract] [Full-text]
34. Antibodies and vaccines--hope or illusion?
    Breast, 14(6): 631-5. [Abstract] [Full-text]
35. Intraoperative electron beam radiotherapy (ELIOT) to the breast: a need for a quality assurance programme.
    Breast, 14(6): 541-6. [Abstract] [Full-text]
36. Prognostic and predictive factors revisited.
    Breast, 14(6): 493-9. [Abstract] [Full-text]
37. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
    Breast, 14(6): 458-65. [Abstract] [Full-text]
38. What extent of radiation therapy is standard?
    Breast, 14(6): 532-40. [Abstract] [Full-text]
39. When mastectomy becomes inevitable: the nipple-sparing approach.
    Breast, 14(6): 527-31. [Abstract] [Full-text]
40. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy.
    Breast, 14(6): 624-30. [Abstract] [Full-text]
41. Predicting response to systemic treatments: learning from the past to plan for the future.
    Breast, 14(6): 582-93. [Abstract] [Full-text]
42. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Breast, 14(6): 466-79. [Abstract] [Full-text]
43. Preoperative (neoadjuvant) systemic treatment of breast cancer.
    Breast, 14(6): 576-81. [Abstract] [Full-text]
44. Special issues related to breast cancer adjuvant therapy in older women.
    Breast, 14(6): 600-11. [Abstract] [Full-text]
45. The biology of steroid hormones and endocrine treatment of breast cancer.
    Breast, 14(6): 452-7. [Abstract] [Full-text]
46. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
    Breast, 14(6): 555-63. [Abstract] [Full-text]
47. Adjuvant chemotherapy in 2005: standards and beyond.
    Breast, 14(6): 439-45. [Abstract] [Full-text]
48. Sentinel lymph node biopsy for localised ductal carcinoma in situ?
    Breast, 14(6): 520-2. [Abstract] [Full-text]
49. Management of women at high risk for breast cancer: new imaging beyond mammography.
    Breast, 14(6): 480-6. [Abstract] [Full-text]
50. Special issues related to the adjuvant therapy in very young women.
    Breast, 14(6): 594-9. [Abstract] [Full-text]
51. When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of the literature.
    Breast, 14(6): 636-42. [Abstract] [Full-text]
52. The best use of adjuvant chemotherapy: new drugs and new use of "old" drugs.
    Breast, 14(6): 570-5. [Abstract] [Full-text]
53. Adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Breast, 14(6): 446-51. [Abstract] [Full-text]
54. Acceptance of adjuvant therapy and quality of life issues.
    Breast, 14(6): 612-6. [Abstract] [Full-text]
55. When will more useful predictive factors be ready for use?
    Breast, 14(6): 617-23. [Abstract] [Full-text]
56. Histopathology of primary breast cancer 2005.
    Breast, 14(6): 487-92. [Abstract] [Full-text]
57. Limiting breast surgery to the proper minimum.
    Breast, 14(6): 523-6. [Abstract] [Full-text]
58. Human cytochrome c enters murine J774 cells and causes G1 and G2/M cell cycle arrest and induction of apoptosis.
    Biochem Biophys Res Commun, 338(2): 1284-90. [Abstract] [Full-text]
59. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.
    Int J Cancer, 118(2): 290-301. [Abstract] [Full-text]
60. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients.
    Int J Cancer, 118(2): 412-21. [Abstract] [Full-text]
61. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
    Int J Cancer, 118(2): 284-9. [Abstract] [Full-text]
62. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis.
    Carcinogenesis, 26(12): 2095-104. [Abstract] [Full-text]
63. MGMT genotype modulates the associations between cigarette smoking, dietary antioxidants and breast cancer risk.
    Carcinogenesis, 26(12): 2131-7. [Abstract] [Full-text]
64. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients.
    Int J Cancer, 118(2): 518-20. [Abstract] [Full-text]
65. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
    J Clin Oncol, 23(33): 8469-76. [Abstract] [Full-text]
66. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.
    J Clin Oncol, 23(33): 8453-60. [Abstract] [Full-text]
67. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
    J Clin Oncol, 23(33): 8340-7. [Abstract] [Full-text]
68. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
    J Clin Oncol, 23(33): 8331-9. [Abstract] [Full-text]
69. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
    J Clin Oncol, 23(33): 8322-30. [Abstract] [Full-text]
70. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    J Clin Oncol, 23(33): 8313-21. [Abstract] [Full-text]
71. Lifetime recreational exercise activity and breast cancer risk among black women and white women.
    J Natl Cancer Inst, 97(22): 1671-9. [Abstract] [Full-text]
72. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    J Natl Cancer Inst, 97(22): 1663-70. [Abstract] [Full-text]
73. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    J Natl Cancer Inst, 97(22): 1652-62. [Abstract] [Full-text]
74. Pregnancy characteristics and maternal risk of breast cancer.
    JAMA, 294(19): 2474-80. [Abstract] [Full-text]
75. Not working 3 years after breast cancer: predictors in a population-based study.
    J Clin Oncol, 23(33): 8305-12. [Abstract] [Full-text]
76. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
    J Clin Oncol, 23(33): 8296-304. [Abstract] [Full-text]
77. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Oncogene, 24(51): 7542-51. [Abstract] [Full-text]
78. Self-report by elderly breast cancer patients was an acceptable alternative to surveillance, epidemiology, and end results (SEER) abstract data.
    J Clin Epidemiol, 58(12): 1316-9. [Abstract] [Full-text]
79. Short-term effects of axillary lymph node clearance surgery on lymphatic physiology of the arm in breast cancer.
    J Appl Physiol, 99(6): 2345-51. [Abstract] [Full-text]
80. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
    Mol Pharmacol, 68(6): 1747-56. [Abstract] [Full-text]
81. The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells.
    Endocrinology, 146(12): 5474-84. [Abstract] [Full-text]
82. Broccoli and watercress suppress matrix metalloproteinase-9 activity and invasiveness of human MDA-MB-231 breast cancer cells.
    Toxicol Appl Pharmacol, 209(2): 105-13. [Abstract] [Full-text]
83. The distinctive role of positron emission tomography/computed tomography in breast carcinoma with brown adipose tissue 2-fluoro-2-deoxy-d-glucose uptake.
    Breast J, 11(6): 457-61. [Abstract] [Full-text]
84. Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer.
    Breast J, 11(6): 448-53. [Abstract] [Full-text]
85. Study of sexual functioning determinants in breast cancer survivors.
    Breast J, 11(6): 440-7. [Abstract] [Full-text]
86. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Breast J, 11(6): 433-9. [Abstract] [Full-text]
87. Quality of life in Brazilian breast cancer survivors age 45-65 years: associated factors.
    Breast J, 11(6): 425-32. [Abstract] [Full-text]
88. The role of ovarian ablation in the management of breast cancer.
    Breast J, 11(6): 416-24. [Abstract] [Full-text]
89. Hormone replacement therapy and breast cancer risk in California.
    Breast J, 11(6): 410-5. [Abstract] [Full-text]
90. Image-guided tissue sampling: where radiology meets pathology.
    Breast J, 11(6): 403-9. [Abstract] [Full-text]
91. An audit of pain/discomfort experienced during image-guided breast biopsy procedures.
    Breast J, 11(6): 398-402. [Abstract] [Full-text]
92. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida.
    Breast J, 11(6): 394-7. [Abstract] [Full-text]
93. Evaluation of the benefit of using blue dye in addition to radioisotope for sentinel lymph node biopsy in patients with breast cancer.
    Breast J, 11(6): 391-3. [Abstract] [Full-text]
94. Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging.
    Breast J, 11(6): 382-90. [Abstract] [Full-text]
95. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    J Steroid Biochem Mol Biol, 97(4): 360-8. [Abstract] [Full-text]
96. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319.
    Int J Radiat Oncol Biol Phys, 63(5): 1531-7. [Abstract] [Full-text]
97. Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy.
    Int J Radiat Oncol Biol Phys, 63(5): 1508-13. [Abstract] [Full-text]
98. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
    J Steroid Biochem Mol Biol, 97(4): 328-41. [Abstract] [Full-text]
99. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Int J Radiat Oncol Biol Phys, 63(5): 1514-21. [Abstract] [Full-text]
100. Comparison of normal tissue dose with three-dimensional conformal techniques for breast cancer irradiation including the internal mammary nodes.
     Int J Radiat Oncol Biol Phys, 63(5): 1522-30. [Abstract] [Full-text]
101. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
     Oncology, 69: 46-56. [Abstract] [Full-text]
102. Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
     Tumour Biol, 26(6): 281-93. [Abstract] [Full-text]
103. Differentiation of benign from malignant solid breast masses: conventional US versus spatial compound imaging.
     Radiology, 237(3): 841-6. [Abstract] [Full-text]
104. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast.
     Br J Cancer, 93(11): 1295-300. [Abstract] [Full-text]
105. Spread of human cancer cells occurs with probabilities indicative of a nongenetic mechanism.
     Br J Cancer, 93(11): 1244-9. [Abstract] [Full-text]
106. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer.
     Br J Cancer, 93(11): 1215-21. [Abstract] [Full-text]
107. Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer.
     Am J Surg, 190(6): 918-22. [Abstract] [Full-text]
108. Total skin-sparing mastectomy without preservation of the nipple-areola complex.
     Am J Surg, 190(6): 907-12. [Abstract] [Full-text]
109. Surgeon and community factors affecting breast cancer sentinel lymph node biopsy.
     Am J Surg, 190(6): 903-6. [Abstract] [Full-text]
110. Breast cancer in Native American women treated at an urban-based Indian health referral center 1982-2003.
     Am J Surg, 190(6): 895-902. [Abstract] [Full-text]
111. Breast cancer in an MSH2 gene mutation carrier.
     Hum Pathol, 36(12): 1322-6. [Abstract] [Full-text]
112. Minimizing local recurrence after breast conserving therapy using intraoperative shaved margins to determine pathologic tumor clearance.
     J Am Coll Surg, 201(6): 855-61. [Abstract] [Full-text]
113. Detection of infraclavicular lymph node metastases using ultrasonography in breast cancer.
     J Surg Oncol, 92(4): 299-303. [Abstract] [Full-text]
114. Non-axillary breast cancer recurrences after sentinel node biopsy.
     J Surg Oncol, 92(4): 292-8. [Abstract] [Full-text]
115. Taxanes in the treatment of early breast cancer.
     Cancer Treat Rev, 31(8): 618-27. [Abstract] [Full-text]
116. A case of advanced Hodgkin lymphoma with breast involvement treated with a combination of gemcitabine and pegylated liposomal doxorubicin.
     Eur J Haematol, 75(6): 515-7. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.